An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Evolus, Inc. (NASDAQ: EOLS) will report its first quarter 2024 financial results on May 7, 2024. The company will host a conference call and webcast to discuss the results. Investors can participate in the call and access the webcast through the Evolus website. A question-and-answer session will follow management's remarks.
Evolus, Inc. (NASDAQ: EOLS) rilascerà i risultati finanziari del primo trimestre 2024 il 7 maggio 2024. La società organizzerà una conferenza telefonica e un webcast per discutere i risultati. Gli investitori possono partecipare alla chiamata e accedere al webcast tramite il sito web di Evolus. Seguirà una sessione di domande e risposte dopo le osservazioni della direzione.
Evolus, Inc. (NASDAQ: EOLS) informará los resultados financieros del primer trimestre de 2024 el 7 de mayo de 2024. La compañía realizará una llamada de conferencia y una transmisión web para discutir los resultados. Los inversores pueden participar en la llamada y acceder a la transmisión web a través del sitio web de Evolus. Una sesión de preguntas y respuestas seguirá a los comentarios de la gerencia.
Evolus, Inc. (나스닥: EOLS)는 2024년 5월 7일에 2024년 첫 분기 재무 결과를 보고할 예정입니다. 회사는 결과를 논의하기 위해 컨퍼런스 콜과 웹캐스트를 개최할 것입니다. 투자자는 Evolus 웹사이트를 통해 콜에 참여하고 웹캐스트에 접속할 수 있습니다. 경영진의 발언 후 질의응답 세션이 이어질 예정입니다.
Evolus, Inc. (NASDAQ: EOLS) publiera ses résultats financiers du premier trimestre 2024 le 7 mai 2024. L'entreprise organisera une conférence téléphonique et une webdiffusion pour discuter des résultats. Les investisseurs peuvent participer à l'appel et accéder à la webdiffusion via le site web d'Evolus. Une session de questions-réponses suivra les remarques de la direction.
Evolus, Inc. (NASDAQ: EOLS) wird am 7. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 bekannt geben. Das Unternehmen wird einen Konferenzanruf und ein Webcast veranstalten, um die Ergebnisse zu diskutieren. Investoren können an dem Anruf teilnehmen und den Webcast über die Evolus-Website abrufen. An die Bemerkungen des Managements schließt sich eine Fragerunde an.
Positive
None.
Negative
None.
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on Tuesday, May 7, 2024, after the U.S. financial markets close.
Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks.
To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here.
Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13746068 An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme®, a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc.
Evolysse™ is a trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
When will Evolus report its first quarter 2024 financial results?
Evolus will report its first quarter 2024 financial results on May 7, 2024.
How can investors participate in the conference call?
Investors can participate in the conference call by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connecting live via webcast on the Investor Relations page of the Evolus website.
Where can investors access the telephonic replay of the conference call?
Investors can access the telephonic replay of the conference call by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13746068.
How can investors access the archived webcast of the conference call?
Investors can access the archived webcast of the conference call on the Investor Relations page of the Evolus website at www.evolus.com.
evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.
